Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced new data demonstrating the anticancer activity of its investigational drug, pralatrexate, in colon ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE